ANTI-DIABETIC ACTIVITY OF TRADITIONAL POLYHERBAL FORMULATION: DEVELOPMENT AND EVALUATION

Herbal therapy has emerged as a prominent therapeutic approach for a wide range of ailments. In tandem with a nutritious diet and lifestyle, these interventions aim to address certain health objectives by supplying each cell with the most suitable and advantageous nourishment. There exists a botanical alternative for each synthetic medicine now available. Material and Methods: The herbs utilized in the formulation were obtained from reputable vendors and subsequently verified by Department of Life Sciences, Garden City University, Bengaluru, Karnataka, India. For the purpose of standardizing raw materials, shade-dried powdered plant parts from the plants Berberis aristata (dried stem), Terminalia chebula (pericarp of matured fruit), Emblica officinalis (pericarp of dried mature fruit), Terminalalia belerica (pericarp of dried ripe fruit), and Cyperus rotundus (dried rhizome) are used. Results: Blood glucose and lipid profiles were taken first thing in the morning. The formulation had a significant impact when compared to the typical range before diabetes was introduced. Total cholesterol, bad LDL cholesterol, and bad triglyceride levels were all reduced while HDL levels were increased. The phytochemical investigation backed up the claim that flavonoids were present. This may explain why it has such a dramatic impact on treating diabetes. It is recommended that future clinical trials be conducted in Human Volunteers, and that stability studies be conducted on the manufactured polyherbal capsules. Conclusion: The oldest type of therapy, herbal remedies are used to identify and treat illnesses. An animal model was used to assess the antidiabetic potency of five raw materials that were chosen for formulation into polyherbal capsules. The capsules significantly improved the lipid profile and fasting blood glucose indices, as well as their anti-diabetic efficacy. Future use is advised to pursue additional stability research and clinical trials

Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future

Introduction: Antibiotics are indispensable to maintaining human health; however, their overuse has resulted in resistant organisms, increasing morbidity, mortality and costs. Increasing antimicrobial resistance (AMR) is a major public health threat, resulting in multiple campaigns across countries to improve appropriate antimicrobial use. This includes addressing the overuse of antimicrobials for self-limiting infections, such as upper respiratory tract infections (URTIs), particularly in lower- and middle-income countries (LMICs) where there is the greatest inappropriate use and where antibiotic utilization has increased the most in recent years. Consequently, there is a need to document current practices and successful initiatives in LMICs to improve future antimicrobial use. Methodology: Documentation of current epidemiology and management of URTIs, particularly in LMICs, as well as campaigns to improve future antimicrobial use and their influence where known. Results: Much concern remains regarding the prescribing and dispensing of antibiotics for URTIs among LMICs. This includes considerable self-purchasing, up to 100% of pharmacies in some LMICs. However, multiple activities are now ongoing to improve future use. These incorporate educational initiatives among all key stakeholder groups, as well as legislation and other activities to reduce self-purchasing as part of National Action Plans (NAPs). Further activities are still needed however. These include increased physician and pharmacist education, starting in medical and pharmacy schools; greater monitoring of prescribing and dispensing practices, including the development of pertinent quality indicators; and targeted patient information and health education campaigns. It is recognized that such activities are more challenging in LMICs given more limited resources and a lack of healthcare professionals. Conclusion: Initiatives will grow across LMICs to reduce inappropriate prescribing and dispensing of antimicrobials for URTIs as part of NAPs and other activities, and these will be monitored